Following a recent decision by the NPPA, the prices of key medications for cholesterol, blood pressure, asthma, and more are ...

Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

Japanese drug major Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), ...

Ceftobiprole has the potential to be used as monotherapy for the treatment of pneumonia and cSSSIs. Patients with DFIs and osteomyelitis were excluded from the cSSSI clinical trials, and ...

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening ...

Years of growing resistance to antibiotics have sparked an urgent global health crisis, giving rise to challenging biological threats and the emergence of more dangerous ...

When compared to COVID test-negative participants, test-positive participants had a significant 3% increase in scores for ...

Since announcing the review, business development at Sandoz has continued, for example with the purchase of GSK's cephalosporin business for up to $500 million. The unit is still facing near-term ...

Out of 175,171 samples, they evaluated 25,491 E coli strains for resistance to several antibiotic classes, focusing on cefovecin, the only third-generation cephalosporin approved for veterinary use.

About Cefiderocol Cefiderocol for injection is a siderophore cephalosporin antibiotic for the treatment of serious ...